Trial · NCT05932849
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Baseline annual exacerbation rate | -12 to 0 months | Baseline frequency and annualized rate of asthma exacerbations by severity levels |
| Primary | Maintenance OCS dose during baseline | -12 to 0 months | Maintenance OCS: frequency of patients on mOCS, dosage (for patients on mOCS), annualized cumulative dose |
| Secondary | Annualised exacerbation rate (AER) | 12 months | AER at 12 months |
| Secondary | Annualised exacerbation rate (AER) | 24 months | AER at 24 months |
| Secondary | FEV1 | 12 months | change in lung function from baseline |
| Secondary | FEV1 | 24 months | change in lung function from baseline |
| Secondary | ACQ-6 | 12 months | Change in asthma control (ACQ-6) score from baseline |
| Secondary | ACQ-6 | 24 months | Change in asthma control (ACQ-6) score from baseline |
| Secondary | AQLQ(S)+12 | 12 months | Change in asthma quality of life (AQLQ) from baseline |
| Secondary | AQLQ(S)+12 | 24 months | Change in asthma quality of life (AQLQ) from baseline |
| Secondary | Eosinophil count | 12 months | Mean change in eosinophil count from baseline |
| Secondary | Eosinophil count | 24 months | Mean change in eosinophil count from baseline |
| Secondary | mOCS dose | 12 months | Percentage change in daily OCS dose, Percentage of patients with OCS \<=5mg/day (only for those patients that at baseline had a daily dose \>5mg/d) |
| Secondary | mOCS dose | 24 months | Percentage change in daily OCS dose, Percentage of patients with OCS \<=5mg/day (only for those patients that at baseline had a daily dose \>5mg/d) |
| Secondary | Treatment persistence | 24 months | Proportion of patients discontinuing benralizumab and proportion by reason for discontinuation |
| Secondary | Adherence to scheduled injections | 24 months | * Frequency of patients taking infections on schedule * Frequency of patients taking injection within +/- 3 days injection window in an observation period * Time between injections |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05932849/registered